Adaptimmune Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Adaptimmune Therapeutics Plc
ADAP Stock  USD 0.08  0.01  15.56%   
Analyzing historical trends in various income statement and balance sheet accounts from Adaptimmune Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Adaptimmune Therapeutics' valuation are summarized below:
Gross Profit
36 M
Profit Margin
(0.39)
Market Capitalization
25.2 M
Enterprise Value Revenue
0.0799
Revenue
179.6 M
There are currently one hundred twenty fundamental signals for Adaptimmune Therapeutics Plc that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Adaptimmune Therapeutics' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 08/07/2025, Market Cap is likely to drop to about 774.7 M. In addition to that, Enterprise Value is likely to drop to about 758.6 M

Adaptimmune Therapeutics Total Revenue

186.93 Million

Check Adaptimmune Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptimmune Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.7 M, Interest Expense of 3.5 M or Selling General Administrative of 41.2 M, as well as many indicators such as Price To Sales Ratio of 0.73, Dividend Yield of 0.0 or PTB Ratio of 22.51. Adaptimmune financial statements analysis is a perfect complement when working with Adaptimmune Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Adaptimmune Stock
Check out the analysis of Adaptimmune Therapeutics Correlation against competitors.

Adaptimmune Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets268.3 M246 M230.4 M
Slightly volatile
Short and Long Term Debt Total77.9 M74.2 M64.8 M
Very volatile
Total Current Liabilities46.5 M64.5 M40.1 M
Slightly volatile
Property Plant And Equipment Net36.3 M51.2 M31.1 M
Slightly volatile
Accounts Payable5.9 M8.7 M5.2 M
Slightly volatile
Cash111.9 M91.1 M96.2 M
Slightly volatile
Non Current Assets Total40.8 M57.8 M35 M
Slightly volatile
Cash And Short Term Investments200.2 M151.6 M172 M
Slightly volatile
Net Receivables14.8 M16 M12.8 M
Slightly volatile
Common Stock Total Equity1.6 M1.5 M821.2 K
Slightly volatile
Liabilities And Stockholders Equity268.3 M246 M230.4 M
Slightly volatile
Non Current Liabilities Total178.1 M169.6 M66.7 M
Slightly volatile
Inventory7.7 M7.3 M1.8 M
Slightly volatile
Other Current Assets12.9 M13.3 M11.1 M
Slightly volatile
Other Stockholder Equity608.9 M1.1 B523.4 M
Slightly volatile
Total Liabilities245.8 M234.1 M107.8 M
Slightly volatile
Property Plant And Equipment Gross126.9 M120.9 M45.3 M
Slightly volatile
Total Current Assets227.5 M188.2 M195.4 M
Slightly volatile
Short Term Debt7 M4.7 M6.6 M
Pretty Stable
Common Stock2.2 M2.1 M935.2 K
Slightly volatile
Common Stock Shares Outstanding264.9 M252.3 M107 M
Slightly volatile
Property Plant Equipment86.4 M82.3 M32.9 M
Slightly volatile
Net Tangible Assets89 M93.7 M132.9 M
Pretty Stable
Short Term Investments108.1 M60.5 M90.8 M
Slightly volatile
Other Liabilities195.8 M186.5 M66.7 M
Slightly volatile
Intangible Assets4.1 M3.9 M1.2 M
Slightly volatile
Capital Surpluse657.5 M1.1 B595.4 M
Slightly volatile
Non Current Liabilities Other4.1 M4.3 M21.1 M
Pretty Stable
Net Invested Capital59 M62.1 M174 M
Slightly volatile
Net Working Capital161 M123.6 M178.9 M
Pretty Stable
Capital Stock1.6 M2.1 M1.2 M
Slightly volatile
Capital Lease Obligations19.6 M24 M24.7 M
Slightly volatile

Adaptimmune Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.7 M11.2 M4.6 M
Slightly volatile
Selling General Administrative41.2 M80.8 M33.2 M
Slightly volatile
Other Operating Expenses128.8 M246.8 M104.3 M
Slightly volatile
Research Development86.3 M149.1 M70.2 M
Slightly volatile
Total Operating Expenses128 M246.7 M103.7 M
Slightly volatile
Total Revenue186.9 M178 M37.4 M
Slightly volatile
Interest Income6.9 M6.6 M2.3 M
Slightly volatile
Net Interest Income2.8 M3.2 M2 M
Slightly volatile
Reconciled Depreciation8.6 M11.2 M6.8 M
Slightly volatile
Selling And Marketing Expenses883.6 K506 K1.6 M
Slightly volatile

Adaptimmune Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation10.9 M12.1 M8.8 M
Slightly volatile
Depreciation5.7 M10.8 M4.5 M
Slightly volatile
Capital Expenditures2.6 M2.7 M6.8 M
Pretty Stable
Total Cash From Financing Activities74.6 M78.7 M80.9 M
Very volatile
Sale Purchase Of Stock3.6 M3.8 M65 M
Very volatile
Change To Netincome12.8 M22 M10.7 M
Slightly volatile
Exchange Rate Changes3.1 M3.8 M2.8 M
Slightly volatile
Issuance Of Capital Stock27.7 M29.2 M102.4 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.730.7634369
Slightly volatile
Days Sales Outstanding31.1332.7662711
Pretty Stable
Average Payables6.3 M6 M5 M
Slightly volatile
Stock Based Compensation To Revenue0.06430.06771.9324
Pretty Stable
Capex To Depreciation0.240.25152.7665
Slightly volatile
EV To Sales4.264.48552.2 K
Slightly volatile
Inventory Turnover0.01040.01144.5137
Slightly volatile
Days Of Inventory On Hand36.1 K34.4 K11.6 K
Slightly volatile
Payables Turnover0.00770.008113.0939
Slightly volatile
Sales General And Administrative To Revenue0.430.45395.494
Very volatile
Average Inventory750.8 K938.7 K1.2 M
Pretty Stable
Research And Ddevelopement To Revenue0.80.837314.6585
Pretty Stable
Capex To Revenue0.01450.01531.1697
Slightly volatile
Cash Per Share0.570.60091.724
Very volatile
Days Payables Outstanding47.6 K45.3 K5.8 K
Slightly volatile
Intangibles To Total Assets0.01660.01580.0048
Slightly volatile
Current Ratio3.752.91614.4116
Pretty Stable
Receivables Turnover10.5811.139571.4688
Slightly volatile
Capex Per Share0.01020.01080.0768
Very volatile
Average Receivables1.7 M3.1 M2.4 M
Slightly volatile
Revenue Per Share0.740.70560.2363
Slightly volatile
Interest Debt Per Share0.450.30740.558
Very volatile
Debt To Assets0.320.30170.3347
Slightly volatile
Operating Cycle40.1 K38.2 K5.6 K
Slightly volatile
Days Of Payables Outstanding47.6 K45.3 K5.8 K
Slightly volatile
Ebt Per Ebit1.080.97790.9859
Pretty Stable
Long Term Debt To Capitalization0.760.730.2667
Slightly volatile
Quick Ratio3.732.80274.3874
Pretty Stable
Net Income Per E B T0.781.05320.9636
Slightly volatile
Cash Ratio2.421.41242.2305
Very volatile
Days Of Inventory Outstanding36.1 K34.4 K11.6 K
Slightly volatile
Days Of Sales Outstanding31.1332.7662711
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.141.03721.0562
Pretty Stable
Fixed Asset Turnover3.653.4760.9904
Slightly volatile
Debt Ratio0.320.30170.3347
Slightly volatile
Price Sales Ratio0.730.7634369
Slightly volatile
Asset Turnover0.760.72380.1473
Slightly volatile

Adaptimmune Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap774.7 M815.5 M2.5 B
Slightly volatile
Enterprise Value758.6 M798.6 M2.4 B
Slightly volatile

Adaptimmune Fundamental Market Drivers

Cash And Short Term Investments151.6 M

Adaptimmune Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Adaptimmune Therapeutics Financial Statements

Adaptimmune Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Adaptimmune Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptimmune Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptimmune Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue12.3 M16.7 M
Cost Of Revenue70 K66.5 K
Total Revenue178 M186.9 M
Stock Based Compensation To Revenue 0.07  0.06 
Sales General And Administrative To Revenue 0.45  0.43 
Research And Ddevelopement To Revenue 0.84  0.80 
Capex To Revenue 0.02  0.01 
Revenue Per Share 0.71  0.74 
Ebit Per Revenue(0.39)(0.41)

Pair Trading with Adaptimmune Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Adaptimmune Stock

  0.55688238 OBiO Technology CorpPairCorr
  0.52JNJ Johnson Johnson Sell-off TrendPairCorr
  0.43ABBV AbbVie IncPairCorr
  0.37ENTA Enanta Pharmaceuticals Earnings Call This WeekPairCorr
  0.33SKYE Skye Bioscience, CommonPairCorr
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY